Yearbook of Oncology10.1016/j.yonc.2012.07.00720122012187-188Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer: A Phase III TrialA.S. Tsao,
The Korean Journal of Internal Medicine10.3904/kjim.2010.25.3.2942010253294Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung CancerJunshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jung, Jae-Ik Lee, Se Hoon Park, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee,,
Journal of Lung Cancer10.6058/jlc.2009.8.2.6120098261Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)Vera Hirsh,,
Yearbook of Oncology10.1016/s1040-1741(08)70163-520062006231-233Erlotinib in-Previously Treated Non-Small-Cell Lung CancerN.H. Hanna,
Yearbook of Pulmonary Disease10.1016/s8756-3452(08)70369-420072007144-146Erlotinib in Previously Treated Non-Small-Cell Lung CancerL.T. Tanoue,
Thoracic Cancer10.1111/j.1759-7714.2012.00152.x201342109-116Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective studyShufei Yu, Yan Wang, Junling Li, Xuezhi Hao, Bin Wang, Ziping Wang, Xiangru Zhang, Yuankai Shi
Current Medicine Research and Practice10.1016/j.cmrp.2016.03.00420166296-97Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer,
Lung Cancer10.1016/j.lungcan.2005.07.0042005503417-418Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancerAvinash Viswanathan, Giancarlo Pillot, Ramaswamy Govindan,
Lung Cancer10.1016/j.lungcan.2011.11.0052012763465-471A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancerMark J.C. Nuijten, Javier de Castro Carpeño, Christos Chouaid, Alain Vergnenègre, Francesco Grossi, Helge Bischoff, David Heigener, Stefan Walzer,
European Journal of Cancer Supplements10.1016/s1359-6349(09)71718-52009725069005 Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trialG.D. Goss, S. Thongprasert, F.A. Greco, M. Thomas, C.M. Tsai, P. Sunpaweravong, D. Ferry, S. Gogov, J.A. Rowbottom, R.B. Natale,